As researchers continue to explore uses for DDA and DIA workflows, mass spec advances are enabling both methods to generate larger and more complete data sets.
The approval covers Waters' Acquity UPLC and Acquity UPLC I-Class systems, as well as its Xevo TQD, Xevo TQ-S micro, and Xevo TQ-S mass spectrometers.
With the exception of Thermo Fisher Scientific, which released three new instruments, vendors focused mainly on expanded applications of existing platforms.
The investment bank took note of Danaher's soft organic growth rate in the first quarter, and said it will need to build up its life science portfolio.
Driven by strong demand from the company's pharma customers, it posted sales of $498 million, beating the average Wall Street estimate of $488.6 million.
A report from Leerink predicted Thermo Fisher Scientific could launch such a system within the next year, potentially opening up the clinical mass spec market.
Researchers at Pacific Northwest National Laboratory are among those pushing ion mobility spectrometry as a tool to boost complex biological sample analysis.
The company's Q4 revenues were $628.8 million, driven largely by strong pharma and industrial sales; full year 2016 revenues were up 6 percent to $2.17 billion.
The bank rated companies like Thermo Fisher Scientific and Agilent at Buy, Illumina and PerkinElmer at Hold, and Myriad Genetics and Luminex at Sell.
The investment bank said the recent pullback in the company's stock has made its valuation more attractive.
Researchers tie a variant in ADAMTS3 to breathing difficulties in dissimilar dog breeds, according to Discover's D-brief blog.
Parents of children with rare genetic disease have to contend with shifts in the interpretation of genetic variants, the Wall Street Journal reports.
The Japan Times reports that researchers sequenced the genome of a woman who lived during the Jomon period.
In Science this week: single-nucleus RNA sequencing of brain tissue from individuals with autism, and more.